Literature DB >> 17928008

Pharmacological and immunological identification of native alpha7 nicotinic receptors: evidence for homomeric and heteromeric alpha7 receptors.

Raed A El-Hajj1, Susan B McKay, Dennis B McKay.   

Abstract

Controversy surrounds the expression of alpha7 nicotinic acetylcholine receptors (nAChRs) in adrenal chromaffin cells. In these studies, alpha7 nAChRs expressed in bovine adrenal chromaffin cells are investigated. Using radiolabeled ligand binding techniques, [(125)I]alpha-bungarotoxin (alphaBGT) binding reaches equilibrium within 4 h and is saturable with a K(d) value of 4.2 nM. Using homologous competition experiments, the K(i) for binding of alphaBGT was 1.9 nM. These data are consistent with the expression of homomeric alpha7 nAChRs. Methyllycaconatine (MLA), which binds alpha7 nAChRs with high affinity, inhibits [(125)I]alphaBGT binding in a concentration-dependent manner with a K(i) of 30.6 nM; this value is approximately 10 fold higher than the reported affinity of MLA for alpha7 nAChRs. We also document the ability of bromoacetylcholine (brACh) to alkylate alpha7 nAChRs, as has been previous demonstrated for bovine adrenal alpha3beta4 nAChRs. When adrenal nAChRs are immunoprecipated with mAb319, an antibody which recognizes alpha7 nAChR protein, and then probed with mAb319 using Western blot analysis, a single band of approximately 53 kDa is identified. When adrenal nAChRs are immunoprecipated with mAb35, an antibody which recognizes alpha3 and alpha5 nAChR proteins, and then probed with mAb319 using Western blot analysis, a single band of approximately 53 kDa is identified. Together, these results support the expression of alpha7 nAChRs in bovine adrenal chromaffin cells. However, these data suggest that the subunit composition of some of these receptors may include heteromeric alpha7 nAChRs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17928008      PMCID: PMC2083560          DOI: 10.1016/j.lfs.2007.08.039

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  31 in total

1.  Pharmacological characterization of recombinant bovine alpha3beta4 neuronal nicotinic receptors stably expressed in HEK 293 cells.

Authors:  R Benjamin Free; Nathaniel D von Fischer; R Thomas Boyd; Dennis B McKay
Journal:  Neurosci Lett       Date:  2003-06-12       Impact factor: 3.046

2.  Physiology and pharmacology of the splanchnic-adrenal medullary junction.

Authors:  E Marley; G I Prout
Journal:  J Physiol       Date:  1965-10       Impact factor: 5.182

3.  Expression of native alpha3beta4* neuronal nicotinic receptors: binding and functional studies investigating turnover of surface and intracellular receptor populations.

Authors:  R Benjamin Free; Susan B McKay; Paul D Gottlieb; R Thomas Boyd; Dennis B McKay
Journal:  Mol Pharmacol       Date:  2005-03-16       Impact factor: 4.436

4.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

5.  [3H]Epibatidine binding to bovine adrenal medulla: evidence for alpha3beta4* nicotinic receptors.

Authors:  R Benjamin Free; Darrell L Bryant; Susan B McKay; Daniel J Kaser; Dennis B McKay
Journal:  Neurosci Lett       Date:  2002-01-25       Impact factor: 3.046

6.  Antagonism of nicotinic receptors of rat chromaffin cells by N,N, N-trimethyl-1-(4-trans-stilbenoxy)-2-propylammonium iodide: a patch clamp and ligand binding study.

Authors:  S Di Angelantonio; A Nistri; M Moretti; F Clementi; C Gotti
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

7.  Structure-activity studies with ring E analogues of methyllycaconitine on bovine adrenal alpha3beta4* nicotinic receptors.

Authors:  Darrell L Bryant; R Benjamin Free; Sara M Thomasy; David J Lapinsky; Khadiga A Ismail; Susan B McKay; Stephen C Bergmeier; Dennis B McKay
Journal:  Neurosci Res       Date:  2002-01       Impact factor: 3.304

8.  Biochemical and histochemical evidence of nonspecific binding of alpha7nAChR antibodies to mouse brain tissue.

Authors:  Donna L Herber; Emily G Severance; Javier Cuevas; Dave Morgan; Marcia N Gordon
Journal:  J Histochem Cytochem       Date:  2004-10       Impact factor: 2.479

9.  Pharmacological properties of rat alpha 7 nicotinic receptors expressed in native and recombinant cell systems.

Authors:  Caterina Virginio; Angelo Giacometti; Laura Aldegheri; Joseph M Rimland; Georg C Terstappen
Journal:  Eur J Pharmacol       Date:  2002-06-12       Impact factor: 4.432

Review 10.  Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.

Authors:  Laura F Martin; William R Kem; Robert Freedman
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

View more
  11 in total

1.  Effect of novel negative allosteric modulators of neuronal nicotinic receptors on cells expressing native and recombinant nicotinic receptors: implications for drug discovery.

Authors:  Tatiana F González-Cestari; Brandon J Henderson; Ryan E Pavlovicz; Susan B McKay; Raed A El-Hajj; Aravinda B Pulipaka; Crina M Orac; Damon D Reed; R Thomas Boyd; Michael X Zhu; Chenglong Li; Stephen C Bergmeier; Dennis B McKay
Journal:  J Pharmacol Exp Ther       Date:  2008-11-04       Impact factor: 4.030

Review 2.  Nicotinic modulation of synaptic transmission and plasticity in cortico-limbic circuits.

Authors:  Huibert D Mansvelder; Marjolijn Mertz; Lorna W Role
Journal:  Semin Cell Dev Biol       Date:  2009-01-22       Impact factor: 7.727

Review 3.  Human nicotinic receptors in chromaffin cells: characterization and pharmacology.

Authors:  Almudena Albillos; J Michael McIntosh
Journal:  Pflugers Arch       Date:  2017-10-20       Impact factor: 3.657

4.  Evidence for the exclusive expression of functional homomeric α7 nAChRs in hypothalamic histaminergic tuberomammillary neurons in rats.

Authors:  Shelley Tischkau; Yashanad Mhaskar; Victor V Uteshev
Journal:  Neurosci Lett       Date:  2014-01-31       Impact factor: 3.046

Review 5.  α7 nicotinic ACh receptors as a ligand-gated source of Ca(2+) ions: the search for a Ca(2+) optimum.

Authors:  Victor V Uteshev
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

6.  Pharmacological characterization of native α7 nicotinic ACh receptors and their contribution to depolarization-elicited exocytosis in human chromaffin cells.

Authors:  Alberto Pérez-Alvarez; Alicia Hernández-Vivanco; Sergio Alonso Y Gregorio; Angel Tabernero; J Michael McIntosh; Almudena Albillos
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

7.  Calcium signalling mediated through α7 and non-α7 nAChR stimulation is differentially regulated in bovine chromaffin cells to induce catecholamine release.

Authors:  Laura del Barrio; Javier Egea; Rafael León; Alejandro Romero; Ana Ruiz; Mayte Montero; Javier Alvarez; Manuela G López
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

8.  A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides.

Authors:  Qiang Liu; Yao Huang; Fenqin Xue; Alain Simard; Jamie DeChon; Guohui Li; Jianliang Zhang; Linda Lucero; Min Wang; Michael Sierks; Gang Hu; Yongchang Chang; Ronald J Lukas; Jie Wu
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

9.  Rat neuronal nicotinic acetylcholine receptors containing alpha7 subunit: pharmacological properties of ligand binding and function.

Authors:  Yingxian Xiao; Galya R Abdrakhmanova; Maryna Baydyuk; Susan Hernandez; Kenneth J Kellar
Journal:  Acta Pharmacol Sin       Date:  2009-05-18       Impact factor: 6.150

10.  Expression of α3β2β4 nicotinic acetylcholine receptors by rat adrenal chromaffin cells determined using novel conopeptide antagonists.

Authors:  Arik J Hone; Lola Rueda-Ruzafa; Thomas J Gordon; Joanna Gajewiak; Sean Christensen; Tino Dyhring; Almudena Albillos; J Michael McIntosh
Journal:  J Neurochem       Date:  2020-02-11       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.